Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 17, 2026

Marrow Therapeutics Raises $173 Million for In Vivo Blood Therapies

Listen
0:00 / 0:00

Key Takeaways

  • Marrow raised $53 million series A (venBio, Scion) and $120 million series B (OrbiMed), adding multiple new institutional investors and notable scientific leadership in hematology and gene regulation.
  • The TAB platform uses engineered TfR1-binding antibodies to deliver therapeutic payloads to bone marrow cells, positioning selective marrow tropism as a strategy to minimize off-target toxicities.
SHOW MORE

Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.

Marrow Therapeutics, a genetic medicines company based in Watertown, Massachusetts, launched on November 17, 2026, with $173 million in combined series A and B financing to develop bone marrow-targeted therapies for severe blood disorders.¹ Its lead candidate, MAR-101, is in investigational new drug application (IND)-enabling studies for sickle cell disease (SCD) and beta thalassemia.¹

Key facts

  • Company: Marrow Therapeutics (Watertown, Massachusetts)
  • Financing: $173 million total ($53 million series A; $120 million series B)
  • Lead investors: Scion Life Sciences and venBio (series A); OrbiMed (series B)
  • Platform: Transferrin Antibody Bioconjugate (TAB), targeting TfR1 in bone marrow
  • Lead candidate: MAR-101 (BCL11A reduction to reactivate fetal hemoglobin)
  • Indications: Sickle cell disease and beta thalassemia
  • Stage: IND-enabling studies
  • Clinical timeline: Clinical entry expected in the coming year, per Scion
  • Leadership: Romesh Subramanian, president and CEO
  • Advisors: Art Levin (board); Stuart Orkin (scientific advisory board)

“We’re at a pivotal moment in genetic medicine and its application in severe blood disorders—the field has validated key targets and shown that genetic approaches can work, but we need to solve the safety and accessibility challenges to truly transform patient outcomes,” said Romesh Subramanian, PhD, Marrow’s president and CEO, in a company press release.¹

Who invested in Marrow?

The $53 million series A was co-led by venBio and Scion Life Sciences, which founded Marrow.¹ OrbiMed led the $120 million series B. All series A investors took part, joined by new investors including RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.¹

Art Levin, founding chief scientific officer of Avidity Biosciences, has joined Marrow’s board. Stuart Orkin, David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School and a Howard Hughes Medical Institute investigator at Boston Children’s Hospital, has joined its scientific advisory board.¹ The leadership team also includes Tim Weeden as chief scientific officer, John Najim as chief operating officer and chief technology officer, and Gavriel Mullokandov as founder and vice president of corporate development.¹

How does Marrow’s platform work?

Marrow’s Transferrin Antibody Bioconjugate (TAB) platform uses engineered antibodies that target the transferrin receptor (TfR1) in bone marrow to deliver therapeutic payloads to bone marrow cells.¹ The company says its approach engages TfR1 while avoiding off-target effects, particularly the anemia risk that limits other TfR1-targeted approaches.¹ That class-level concern has been documented preclinically. In a 2013 study of TfR bispecific antibodies designed to cross the blood-brain barrier, researchers observed decreased circulating reticulocytes after dosing. Eliminating the antibodies’ Fc effector function partially rescued that decrease.²

MAR-101 is designed to decrease BCL11A and reactivate fetal hemoglobin production, a single approach the company is applying to both SCD and beta thalassemia.¹ BCL11A is a well-characterized regulator of fetal hemoglobin. Research co-authored by Orkin showed that an erythroid enhancer of BCL11A, which is subject to genetic variation, determines fetal hemoglobin levels.³

Why does in vivo delivery matter?

Marrow’s in vivo approach aims to overcome limits of earlier genetic medicine approaches, including safety concerns, manufacturing complexity, and patient access.¹ The ex vivo gene therapies approved for SCD require collecting a patient’s own stem cells, and patients must undergo myeloablative conditioning with high-dose chemotherapy before receiving the modified cells.⁴ One of those therapies, exagamglogene autotemcel (Casgevy), was approved by FDA in December 2023 as the first CRISPR/Cas9-based therapy, and it works by increasing fetal hemoglobin production.⁴

“Marrow has optimized its proprietary bone marrow-targeting platform using lessons learned from validated first-generation TfR1 platforms targeting other tissues and organs,” said Aaron Kantoff, cofounder and managing partner at Scion Life Sciences, in the release.¹ He added that Scion expects Marrow to move its programs into the clinic in the coming year.¹

What are the limitations?

MAR-101 has not yet entered clinical testing. The release does not disclose preclinical data, the payload modality, a timeline for the investigational new drug application, or the specific additional indications in Marrow’s pipeline. The company’s claims that the platform avoids the anemia risk of other TfR1-targeted approaches and overcomes the limits of ex vivo therapies have not been shown in humans. Marrow did not disclose its valuation or how the financing will be split across programs.

References

  1. Marrow Therapeutics. Marrow Therapeutics launches with $173 million to develop genetic medicines for bone marrow disorders. Press release. Published November 17, 2026. Accessed November 17, 2026. https://www.marrowtx.com/news/marrow-therapeutics-launches-with-173-million-to-develop-genetic-medicines-for-bone-marrow-disorders/
  2. Couch JA, Yu YJ, Zhang Y, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013;5(183):183ra57. doi:10.1126/scitranslmed.3005338
  3. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342(6155):253-257. doi:10.1126/science.1242088
  4. FDA. FDA approves first gene therapies to treat patients with sickle cell disease. News release. December 8, 2023. Accessed November 17, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

Related to this article